The essential meaning of determining the NTRS is the combination of PD-L1 expression to completely assess the prognosis and treatment responsiveness of NSCLC patients, as well as predominant benefit/cost proportion. This evidence concerns the gene CD274 and non-small cell lung carcinoma.